Table 2.
RA patient's characteristics when serum samples were collected.
| Total RA patients, n = 62 (42.9%) | |
|---|---|
| Gender: female, n (%) | 51 (82.3) |
| Median age, years, mean ± SD | 50.65 ± 13.47 |
| Months of treatment, when blood samples were collected, median (IQR) (interval): | |
| ADA | 6 (3–9) (3–84) |
| ETA | 30 (3–54) (3–66) |
| INF | 15 (12–51) (6–102) |
| Number of performed tests, n (%) | |
| ADA | 9 (14.5) |
| ETA | 29 (46.8) |
| INF | 24 (38.7) |
| RF positive, n (%) | 58 (93.5) |
| ACCP positive, n (%) | 26 (41.9) |
| Erosive disease, n (%) | 62 (100.0) |
| TJC-60, median (IQR) | 4 (2–12) |
| SJC-60, median (IQR) | 3 (1–8) |
| Doctor's GDA, mm, mean ± SD | 26.48 ± 17.8 |
| Patient's GDA, mm, median (IQR) | 36.0 (13.0–56.0) |
| DAS28, mean ± SD | 3.44 ± 1.69 |
| SDAI, median (IQR) | 12.5 (6.0–24.6) |
| HAQ, median (IQR) | 1.0 (0.373–1.38) |
| ESR, mm/h, median (IQR) | 15 (8–27) |
| CRP, mg/L, median (IQR) | 2.5 (1.2–5.7) |
| DMARDs use, n (%) | 50 (80.6) |
| MTX use, n (%) | 43 (69.4) |
| Medium MTX dose, mg/week, mean ± SD | 11.22 ± 4.38 |
| GK use, n (%) | 45 (72.6) |
| Prednisolone equivalent dose, mg/d, mean ± SD | 7.49 ± 3.35 |
Notes: data presented mean ± standard deviation or median and interquartile range (IQR) or number (n) and percent of total number of patients;
Abbreviations: RA: rheumatoid arthritis; IQR: interquartile range; SD: standard deviation, TJC-60: 60 tender joint count, SJC-60: 60 swollen joint count, GDA:global disease activity visual analogue scale (0–100 mm), RF: IgM rheumatoid factor; ACCP: cyclic citrullinated peptide antibody, DAS28: disease activity score in 28 joints; SDAI: simplified disease activity index; HAQ: Health Assessment Questionnaire, ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DMARDs: disease-modifying antirheumatic drugs (e.g., methotrexate, sulfasalazine, leflunomide, hydrochloroquine, and azathioprine); MTX: methotrexate, and na: data is not applicable.